NSE filing, NSE: MAXHEALTH. Summary written from the filing by ALFA Finder's alert engine.
Max Healthcare Institute Ltd: key numbers
- Share price
- ₹851.15
- Market cap
- ₹82,843 Cr
- Revenue (annual)
- ₹8,373 Cr
- Net profit (annual)
- ₹1,442 Cr
- P/E (TTM)
- 56.9×Sector 52.3×
- Promoter holding
- 23.71%+0.00% QoQ
- FII holding
- 40.52%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Max Healthcare Institute Ltd
All →Max Healthcare Institute Legal & Regulatory
Max Healthcare informed the Exchange that the NCLT hearing regarding petitions against its subsidiary, Kalinga Hospital Ltd., was adjourned to October 30, 2026.
Max Healthcare Institute Annual General Meeting
Max Healthcare shareholders approved special resolutions by postal ballot on 19-Oct-2026. These cover a PRSU scheme for up to 73.5 lakh shares, remuneration for the Chairman and MD, and an alteration of the MoA objects clause.
Max Healthcare Institute Board Meeting Date
Max Healthcare's board meets on 30-Oct-2026 to consider unaudited quarterly and half-year results. The trading window stays closed until 48 hours after results.
Max Healthcare Institute Employee Stock Options
Max Healthcare Institute Limited has instituted the MHIL PRSU Scheme 2026. The scheme covers up to 73.50 lakh equity shares for employee stock-based incentives.
Max Healthcare Institute Annual General Meeting
Max Healthcare Institute announced the postal ballot voting results. Shareholders approved the Performance Linked Restricted Stock Unit Scheme 2026 and other special resolutions.
Max Healthcare Institute Other Announcement
Max Healthcare Institute Limited received an independent ESG rating of '66' from NSE Sustainability Ratings and Analytics. The rating for FY 2025-26 was assigned based on public disclosures.
Other credit rating announcements
All →Epigral Credit Rating
CRISIL revised Epigral's ratings to CRISIL AA/Stable (long-term) and CRISIL A1+ (short-term) on its bank facilities. The action covers Rs.1,050 Crore of rated bank loan facilities.
Mankind Pharma Credit Rating
CRISIL reaffirmed Mankind Pharma's AA+ rating on Rs.2,500 Crore of NCDs and withdrew ratings on Rs.2,500 Crore NCDs and Rs.1,500 Crore commercial paper. The rating action is dated October 29, 2026.
Lloyds Metals & Energy Credit Rating
Crisil Ratings reaffirmed Lloyds Metals' bank facilities at AA/Stable and A1+, with bank limits enhanced to ₹17,112 crore. It assigned AA/Stable to ₹2,400 crore and ₹1,550 crore of NCDs.
Ram Ratna Wires Credit Rating
CARE Ratings assigned and reaffirmed Ram Ratna Wires' bank facility ratings at CARE A-; Positive / CARE A2+ and revised outlook from Stable to Positive. The long-term bank facilities total Rs.1,046.45 Crore, with several facilities enhanced.
Adani Ports & Special Economic Zone Credit Rating
Fitch Ratings affirmed Adani Ports' Long-Term Foreign-Currency IDR and unsecured notes at 'BBB-' with a Stable outlook. The affirmation keeps the existing rating unchanged.
Capri Global Capital Credit Rating
India Ratings affirmed CGCL's credit rating at IND AA- with Positive outlook. A new Rs. 500 Cr bank loan facility was also assigned the same rating.